Current and Emerging Systemic Therapies for Hepatocellular Carcinoma: Clinical Evidence and Guideline Recommendations

The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with HCC.

Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC

Target Audience

This educational program is intended for medical oncologists, surgical oncologists, pathologists, physician assistants, nurses, pharmacists, and other healthcare professionals who treat patients with HCC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate clinical data on the use of systemic treatment approaches for patients with early or intermediate-stage HCC
  • Plan optimal, individualized care plans for patients with advanced HCC, both in the frontline and second-line treatment settings
  • Select patients who may benefit from ongoing clinical trials based on tumor characteristics, previous treatment, and patient characteristics and preferences
  • Develop strategies to identify and mitigate unique adverse events associated with novel targeted therapies in patients with HCC
Additional information

Supported by educational grants from:

  • AstraZeneca
  • Eisai

Supported by a medical education grant from Exelixis, Inc.

Supported by an independent educational grant from Merck  & Co., Inc.

Course summary
Available credit: 
  • 1.50 AAPA Category 1 CME credit
  • 1.50 ACPE contact hours
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC contact hours
  • 1.50 Participation
Course opens: 
Course expires: 

Adam M. Burgoyne, MD, PhD
Assistant Clinical Professor of Medicine
Division of Hematology/Oncology
Co-leader, Gastrointestinal Disease Team Moores Cancer Center
University of California San Diego Health
San Diego, California

Lipika Goyal, MD, MPhil
Lead of the Liver Cancer Research Program
Assistant Professor of Medicine
Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Stacey Stein, MD
Associate Professor of Medicine 
Department of Medical Oncology
Yale University
Medical Oncologist
GI Oncology
Yale Cancer Center
New Haven, Connecticut


NCCN Medical Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 


Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below has the following relevant financial relationships with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Adam M. Burgoyne, MD, PhD
Deciphera Pharmaceuticals, Inc.: Consulting Fee 
Exelixis Inc.: Consulting Fee
Genentech, Inc.: Consulting Fee

Lipika Goyal, MD, MPhil
Adaptimmune Therapeutics: Grant/Research Support 
Alentis Therapeutics: Consulting Fee
AstraZeneca Pharmaceuticals LP: Consulting Fee 
Bayer HealthCare: Grant/Research Support
Black Diamond Therapeutics, Inc.: Consulting Fee
Bristol-Myers Squibb Company: Grant/Research Support 
Eisai Inc.: Grant/Research Support
Eli Lilly and Company: Grant/Research Support
Exelixis Inc.: Consulting Fee
Genentech, Inc.: Grant/Research Support 
H3 Biomedicine Inc.: Consulting Fee
Incyte Corporation: Consulting Fee; Grant/Research Support
Leap Therapeutics, Inc.: Grant/Research Support
Loxo Oncology, Inc.: Grant/Research Support 
MacroGenics, Inc.: Grant/Research Support
Merck & Co., Inc.: Grant/Research Support
Novartis  Pharmaceuticals Corporation: Grant/Research Support
NuCana: Grant/Research Support 
QED Therapeutics: Consulting Fee; Grant/Research Support
Relay Therapeutics: Grant/Research Support
Servier Pharmaceuticals LLC: Consulting Fee; Grant/Research Support
Sirtex Medical: Consulting Fee 
Taiho Pharmaceuticals Co., Ltd.: Consulting Fee; Grant/Research Support

Stacey M. Stein, MD
AstraZeneca Pharmaceuticals LP: Consulting Fee 
Eisai Inc.: Consulting Fee 
Genentech, Inc.: Consulting Fee
Merck & Co., Inc.: Consulting Fee
QED Therapeutics: Consulting Fee

NCCN and CCO Staff Disclosures

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.


In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NCCN designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NCCN designates this educational activity for a maximum of 1.5 contact hours.

NCCN designates this application-based continuing education activity for 1.5 contact hours (0.15 CEUs) of continuing education credit. UAN: JA4008196-0000-22-027-H01-P

Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until March 1, 2023. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 1.50 AAPA Category 1 CME credit
  • 1.50 ACPE contact hours
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC contact hours
  • 1.50 Participation


Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing